Sarepta Therapeutics Inc. (SRPT)
What Makes Sarepta Therapeutics (SRPT) a New Buy Stock
Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity
Sarepta Therapeutics, Inc. is a leader in DMD treatment, with recent FDA approval for SRP-9001 gene therapy across all age groups. Despite a recent stock pullback, the company reported strong revenue growth and earnings, with a $130 billion cumulative U.S. revenue opportunity. The recent pullback is an attractive investment opportunity for long-term investors.
Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 38.04%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 38% in Sarepta Therapeutics (SRPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What Makes Sarepta Therapeutics (SRPT) a Strong Momentum Stock: Buy Now?
Does Sarepta Therapeutics (SRPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
Sarepta (SRPT) surges on the commercial potential of its Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy.
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
Sarepta Therapeutics just received expanded labeling for one of its therapies. But the therapy has not performed as well as expected in clinical trials.
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
Previously, Sarepta's gene therapy treatment Elevidys was approved for only a limited number of Duchenne muscular dystrophy patients. Regulators, however, have expanded that range, and it can now be used to treat patients who are 4 and older.
1 Soaring Growth Stock to Buy and Hold for 10 Years
Sarepta Therapeutics' most important medicine now looks even more promising. The biotech's financial results are improving substantially.
Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?
Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Sarepta Therapeutics: Pushing The Edge And Creating The Horizon
Sarepta Therapeutics excels in rare disease therapies using RNA, gene editing, and gene therapies, with significant revenue growth driven by ELEVIDYS gene therapy approval. Despite missing the primary endpoint, ELEVIDYS hit key secondary endpoints, leading to FDA approval for all DMD patients ages 4 and older. Now with a label that covers roughly 80% of the DMD population, Sarepta is positioned for explosive growth in the DMD market.
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.
Sarepta Therapeutics Stock Soars on FDA Approval
Sarepta Therapeutics NASDAQ: SRPT is leading the game in precision genetic medicine and biotechnology. Sarepta Therapeutics' stock price has witnessed a surge of over 40% after receiving expanded FDA approval for its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys.
